FR06C0021I2 - Complexes a base de ligands d'acide nucleique de facteur de croissance endothelial vasculaire - Google Patents

Complexes a base de ligands d'acide nucleique de facteur de croissance endothelial vasculaire

Info

Publication number
FR06C0021I2
FR06C0021I2 FR06C0021C FR06C0021C FR06C0021I2 FR 06C0021 I2 FR06C0021 I2 FR 06C0021I2 FR 06C0021 C FR06C0021 C FR 06C0021C FR 06C0021 C FR06C0021 C FR 06C0021C FR 06C0021 I2 FR06C0021 I2 FR 06C0021I2
Authority
FR
France
Prior art keywords
nucleic acid
acid ligand
growth factor
vascular endothelial
endothelial growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR06C0021C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/739,109 external-priority patent/US5859228A/en
Priority claimed from US08/870,930 external-priority patent/US6168778B1/en
Priority claimed from US08/897,351 external-priority patent/US6051698A/en
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of FR06C0021I1 publication Critical patent/FR06C0021I1/fr
Application granted granted Critical
Publication of FR06C0021I2 publication Critical patent/FR06C0021I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
FR06C0021C 1996-10-25 2006-07-03 Complexes a base de ligands d'acide nucleique de facteur de croissance endothelial vasculaire Active FR06C0021I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/739,109 US5859228A (en) 1995-05-04 1996-10-25 Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US08/870,930 US6168778B1 (en) 1990-06-11 1997-06-06 Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
US08/897,351 US6051698A (en) 1997-06-06 1997-07-21 Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
PCT/US1997/018944 WO1998018480A1 (en) 1996-10-25 1997-10-17 Vascular endothelial growth factor (vegf) nucleic acid ligand complexes

Publications (2)

Publication Number Publication Date
FR06C0021I1 FR06C0021I1 (ja) 2006-10-13
FR06C0021I2 true FR06C0021I2 (fr) 2007-08-03

Family

ID=27419245

Family Applications (1)

Application Number Title Priority Date Filing Date
FR06C0021C Active FR06C0021I2 (fr) 1996-10-25 2006-07-03 Complexes a base de ligands d'acide nucleique de facteur de croissance endothelial vasculaire

Country Status (18)

Country Link
EP (2) EP0957929B1 (ja)
JP (2) JP3626503B2 (ja)
KR (1) KR100514929B1 (ja)
AT (1) ATE318143T1 (ja)
AU (1) AU733674B2 (ja)
CA (1) CA2269072C (ja)
DE (3) DE122006000029I2 (ja)
DK (1) DK0957929T3 (ja)
ES (1) ES2259188T3 (ja)
FR (1) FR06C0021I2 (ja)
GE (1) GEP20094799B (ja)
IL (2) IL129497A0 (ja)
LU (1) LU91252I2 (ja)
NL (1) NL300234I2 (ja)
NZ (1) NZ334859A (ja)
PT (1) PT957929E (ja)
RU (1) RU2177950C2 (ja)
WO (1) WO1998018480A1 (ja)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346611B1 (en) * 1990-06-11 2002-02-12 Gilead Sciences, Inc. High affinity TGfβ nucleic acid ligands and inhibitors
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US6232071B1 (en) * 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
AU782620B2 (en) * 1991-06-10 2005-08-11 Gilead Sciences, Inc. High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
US6762290B1 (en) * 1999-07-29 2004-07-13 Gilead Sciences, Inc. High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
BR0012443A (pt) * 1999-07-14 2002-04-02 Alza Corp Lipolìmero neutro e composições de lipossoma contendo o mesmo
EP2322648A1 (en) * 2000-09-26 2011-05-18 Duke University RNA aptamers and methods for identifying the same
US7629456B2 (en) * 2001-10-26 2009-12-08 Noxxon Pharma Ag Modified L-nucleic acid
OA12720A (en) * 2001-11-09 2006-06-27 Eyetech Pharmaceuticals Methods for treating ocular neovascular diseases.
US7767803B2 (en) 2002-06-18 2010-08-03 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
JP2005533862A (ja) 2002-07-25 2005-11-10 アーケミックス コーポレイション 調節されたアプタマー治療剤
US9303262B2 (en) 2002-09-17 2016-04-05 Archemix Llc Methods for identifying aptamer regulators
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US10100316B2 (en) 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
US8039443B2 (en) 2002-11-21 2011-10-18 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
WO2004050899A2 (en) 2002-12-03 2004-06-17 Archemix Corporation Method for in vitro selection of 2’-substituted nucleic acids
FR2852606A1 (fr) * 2003-03-18 2004-09-24 Inst Nat Sante Rech Med Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie
EP1620547B1 (en) 2003-04-21 2014-06-18 Archemix LLC Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
CL2004001996A1 (es) * 2003-08-08 2005-05-06 Eyetech Pharmaceuticals Inc Aptameros anti-vegf (factor de crecimiento endotelial vascular) con bloqueo nucleotidico 5'-5' o 3'-3' invertido, composicion que lo contiene, util para trastornos de neovascularizacion.
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
WO2005079363A2 (en) 2004-02-12 2005-09-01 Archemix Corporation Aptamer therapeutics useful in the treatment of complement-related disorders
BRPI0509911A (pt) * 2004-04-13 2007-09-18 Osi Eyetech Inc método para inibir a atividade de um sìtio separado de um sìtio de ligação de aptámero em um ligando, métodos para aumentar a faixa antagonista, de receptor de um aptámero de ligação de ligando, do ligando de um aptámero de ligação de receptor, de receptor de um aptámero de vegf, e do ligando de um aptámero de vegfr, método para aumentar uma propriedade antagonista de um aptámero que alveja uma proteìna que interage com uma segunda proteìna, método para identificar um conjugado de aptámero, composto, métodos para liberar uma molécula biologicamente ativa, ácido nucléico, um aptámero, e um aptámero anti-vegf a um olho, composto, composição para liberar uma molécula biologicamente ativa a um olho
US7579450B2 (en) 2004-04-26 2009-08-25 Archemix Corp. Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
EP1807107B1 (en) 2004-11-02 2011-09-07 Archemix Corp. Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US8101385B2 (en) 2005-06-30 2012-01-24 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
AU2006265896B2 (en) 2005-06-30 2012-05-31 Archemix Corp. Materials and methods for the generation of fully 2'-modified nucleic acid transcripts
JP2009510182A (ja) * 2005-07-28 2009-03-12 （オーエスアイ）アイテツク・インコーポレーテツド シクリトールリンカーポリマー抱合体
WO2007024707A2 (en) 2005-08-22 2007-03-01 The Regents Of The University Of California Tlr agonists
KR100877824B1 (ko) 2005-11-11 2009-01-12 한국생명공학연구원 Ｅ2ｅｐｆ ｕｃｐ-ｖｈｌ 상호작용 및 그 용도
CA2632417A1 (en) * 2005-12-06 2007-06-14 Domantis Limited Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
EP1968643A2 (en) * 2005-12-16 2008-09-17 Diatos Cell penetrating peptide conjugates for delivering of nucleic acids into a cell
EP1970078A4 (en) * 2006-01-11 2010-11-17 Kyowa Hakko Kirin Co Ltd COMPOSITION FOR INHIBITING A TARGET GENE IN AN EYEBORN AND REMEDY FOR ACAPIC DISEASE
JP5406534B2 (ja) 2006-03-08 2014-02-05 アーケミックス エルエルシー 補体結合アプタマーおよび眼障害の処置において有用な抗ｃ５剤
PT2510946E (pt) 2007-02-07 2015-11-23 Univ California Conjugados de agonistas sintéticos de tlr e suas utilizações
WO2009137095A2 (en) 2008-05-08 2009-11-12 The Johns Hopkins University Compositions and methods for modulating an immune response
WO2010065671A2 (en) * 2008-12-04 2010-06-10 Curna, Inc. Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
CN104922676B (zh) 2009-03-20 2019-03-12 Clsn实验室股份有限公司 聚胺衍生物
EP2504436A1 (en) 2009-11-23 2012-10-03 INSERM - Institut National de la Santé et de la Recherche Médicale Aptamers directed against the matrix protein-1 of type a influenza viruses and uses thereof
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
WO2012040524A1 (en) * 2010-09-24 2012-03-29 Mallinckrodt Llc Aptamer conjugates for targeting of therapeutic and/or diagnostic nanocarriers
WO2013153138A1 (en) 2012-04-11 2013-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Matrix metalloproteinase 9 (mmp-9) aptamer and uses thereof
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
AU2013340414B2 (en) 2012-10-23 2019-05-02 Caris Science, Inc. Aptamers and uses thereof
CA2895847C (en) 2012-12-19 2019-01-08 Caris Science, Inc. Compositions and methods for aptamer screening
WO2014148638A1 (ja) 2013-03-22 2014-09-25 国立大学法人東京大学 Ｉｌ－１７に対するアプタマー及びその使用
SG10201708882TA (en) 2013-07-12 2017-12-28 Ophthotech Corp Methods for treating or preventing ophthalmological conditions
BR112016004153A2 (pt) 2013-08-28 2019-09-17 Caris Life Sciences Switzerland Holdings Gmbh "método para caracterizar uma doença ou distúrbio, kit, composição, método para gerar uma biblioteca de entrada, oligonucleotídeo, pluralidade de oligonucleotídeos e método para identificar um aptâmero
CN114306575A (zh) 2014-12-11 2022-04-12 拜耳医药保健有限责任公司 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
KR102585112B1 (ko) 2014-12-29 2023-10-10 도레이 카부시키가이샤 핵산 분자를 안정하게 포함하는 조성물
AU2016229076B2 (en) 2015-03-09 2022-01-20 Caris Science, Inc. Oligonucleotide probes and uses thereof
AU2016287499B2 (en) 2015-06-29 2022-08-04 Caris Science, Inc. Therapeutic oligonucleotides
AU2016298317B2 (en) 2015-07-28 2021-02-18 Caris Science, Inc. Targeted oligonucleotides
WO2017046140A1 (en) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
WO2017161357A1 (en) 2016-03-18 2017-09-21 Caris Science, Inc. Oligonucleotide probes and uses thereof
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
US11293017B2 (en) 2016-05-25 2022-04-05 Caris Science, Inc. Oligonucleotide probes and uses thereof
EP3332812A1 (en) 2016-12-07 2018-06-13 Rheinische Friedrich-Wilhelms-Universität Bonn Nucleic acid-based assembly and use of the assembly in cancer therapy
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
US11931327B2 (en) 2017-07-04 2024-03-19 Daiichi Sankyo Company, Limited Drug for retinal degenerative disease associated with photoreceptor degeneration
WO2019210097A1 (en) * 2018-04-25 2019-10-31 Vitrisa Therapeutics, Inc. Aptamers with stability, potency or half-life for enhanced safety and efficacy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0462145T3 (da) * 1989-03-07 1994-08-08 Genentech Inc Covalente konjugater mellem lipid og oligonucleotid
US5849479A (en) * 1990-06-11 1998-12-15 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US5459015A (en) * 1990-06-11 1995-10-17 Nexstar Pharmaceuticals, Inc. High-affinity RNA ligands of basic fibroblast growth factor
US5811533A (en) * 1990-06-11 1998-09-22 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US6168778B1 (en) * 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes

Also Published As

Publication number Publication date
DE122006000029I2 (de) 2007-11-08
ATE318143T1 (de) 2006-03-15
IL129497A (en) 2009-06-15
DE69735292D1 (de) 2006-04-27
PT957929E (pt) 2006-06-30
FR06C0021I1 (ja) 2006-10-13
AU733674B2 (en) 2001-05-24
CA2269072A1 (en) 1998-05-07
GEP20094799B (en) 2009-10-26
NL300234I1 (nl) 2006-09-01
NL300234I2 (nl) 2006-10-02
IL129497A0 (en) 2000-02-29
JP2005046160A (ja) 2005-02-24
KR20000052697A (ko) 2000-08-25
KR100514929B1 (ko) 2005-09-15
JP3626503B2 (ja) 2005-03-09
EP0957929B1 (en) 2006-02-22
EP0957929A4 (en) 2003-06-25
JP4160038B2 (ja) 2008-10-01
LU91252I2 (fr) 2006-08-14
ES2259188T3 (es) 2006-09-16
RU2177950C2 (ru) 2002-01-10
EP1685842A2 (en) 2006-08-02
DE122006000029I1 (de) 2006-10-19
CA2269072C (en) 2006-02-14
JP2001505191A (ja) 2001-04-17
DE69735292T2 (de) 2006-10-19
EP0957929A1 (en) 1999-11-24
NZ334859A (en) 2001-02-23
EP1685842A3 (en) 2006-11-29
WO1998018480A1 (en) 1998-05-07
DK0957929T3 (da) 2006-07-03
AU4990497A (en) 1998-05-22

Similar Documents

Publication Publication Date Title
FR06C0021I2 (fr) Complexes a base de ligands d'acide nucleique de facteur de croissance endothelial vasculaire
DE69638099D1 (de) Nukleinsäureligand-komplexe
DE69109131T2 (de) Verfahren zur herstellung von molekularsieben, einschliesslich zeolithen, mit metallchelat-komplexen.
GR3008515T3 (ja)
DE69017398D1 (de) Buschmäher.
DK0705846T3 (da) Höjmolekylære og lavmolekylære fraktioner af von Willebrand-faktor
DE59001438D1 (de) Verfahren zur herstellung von tetrabrom-4,4'-alkyliden-diphenolen.
FI893428A0 (fi) Eliminering av toxiska egenskaper in vitro och in vivo hos tnf-a medelst monoklonala antikroppar och fragment haerledda fraon dessa.
DE60045577D1 (de) Von willebrand-faktor-aktivitätsnachweis
DE69101708T2 (de) Verfahren zur herstellung von übergangsmetallnitridkomplexen.
DK0570575T3 (da) Bicykloazamakrocyklophosphonsyre, komplekser, konjugater, kontrastmidler og fremstilling heraf
DE69806164T2 (de) Verfahren zur herstellung von polyanilin mit hohem molekulargewicht in seiner emeraldinform
DE59001106D1 (de) Verfahren zur herstellung von 1,1,1-trifluor-2-chlorethan.
DE68907897T2 (de) Selbstschmierendes Lager.
DE59008750D1 (de) Verfahren zur Herstellung von Ironen.
DE69012103D1 (de) Verfahren zur herstellung von 4,4'-diisopropylbiphenyl.
DE59002140D1 (de) Verfahren zur herstellung von 2,3,5-trimethyl-p-benzochinon.
IT8720256A0 (it) Complessi di b- ciclodestrina adattivita' antimicotica.
DE59804233D1 (de) Verfahren zur Herstellung von Formylimidazolen
DE59002719D1 (de) Ringkernlager zur Abstützung von Antriebsaggregaten in Kraftfahrzeugen.
SI0957929T1 (sl) Kompleksi liganda nukleinske kisline vaskularnegaendotelijskega rastnega faktorja (VEGF)
IT1256078B (it) Ligandi kit solubili
DE59106957D1 (de) Verfahren zur herstellung von trans-3,3,5-trimethylcyclohexylethylether.
ATE89284T1 (de) Aminoanthracendion-bis-platinkomplexe, nuetzlich als antitumor-agenzien.
FI102459B1 (fi) Menetelmä vesiliukoisen silybiniinin inkluusiokompleksien valmistamiseksi